ZTSNYSEPharmaceutical PreparationsFiscal year ends December 31
Zoetis Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$79.59+0.21 (+0.26%)
Close on Oct 19, 2026
- Market cap
- $33.24B
- P/E (TTM)
- 13.1
- Dividend yield
- 2.55%
Zoetis Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S. | $5.10B | $5.07B | $4.56B | $4.31B | $4.04B | $3.56B | $3.20B | $2.88B | $2.62B | $2.45B | 53.8% | +0.5% |
| International | $4.25B | $4.10B | $3.91B | $3.68B | $3.65B | $3.04B | $2.97B | $2.89B | $2.64B | $2.39B | 44.9% | +3.7% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total products and services | $9.35B | $9.18B | $8.47B | $7.99B | $7.69B | $6.59B | $6.18B | $5.77B | $5.26B | $4.84B | 98.8% | +1.9% |
| Companion animal | $6.59B | $6.28B | $5.58B | $5.20B | $4.69B | $3.65B | $3.15B | $2.61B | $2.23B | $1.96B | 69.6% | +4.9% |
| Horses | $6.28B | $5.99B | $5.29B | $4.94B | $4.43B | $3.44B | $2.95B | $2.45B | $2.08B | $1.81B | 66.4% | +4.8% |
| Livestock | $2.76B | $2.90B | $2.89B | $2.79B | $3.01B | $2.94B | $3.03B | $3.15B | $3.04B | $2.88B | 29.2% | -4.6% |
| Parasiticides | $2.34B | $2.15B | $1.95B | $1.86B | $1.64B | $1.17B | $966.00M | $836.00M | $763.00M | $659.00M | 24.7% | +8.7% |
| Vaccines | $1.96B | $1.83B | $1.77B | $1.72B | $1.67B | $1.48B | $1.48B | $1.49B | $1.37B | $1.25B | 20.7% | +7.2% |
| Dermatology | $1.75B | $1.66B | $1.43B | $1.33B | $1.18B | $941.00M | $770.00M | $607.00M | $428.00M | – | 18.5% | +6.0% |
| Cattle | $1.49B | $1.53B | $1.50B | $1.44B | $1.56B | $1.56B | $1.65B | $1.75B | $1.74B | $1.65B | 15.8% | -2.5% |
| Anti-infectives | $1.04B | $1.10B | $1.06B | $1.08B | $1.22B | $1.21B | $1.25B | $1.28B | $1.25B | $1.26B | 10.9% | -5.8% |
| Pain and sedation | $840.00M | $851.00M | $602.00M | $420.00M | – | – | – | – | – | – | 8.9% | -1.3% |
| Other pharmaceutical | $697.00M | $658.00M | $678.00M | $623.00M | $966.00M | $821.00M | $780.00M | $765.00M | $753.00M | $988.00M | 7.4% | +5.9% |
| Swine | $466.00M | $516.00M | $543.00M | $565.00M | $659.00M | $621.00M | $611.00M | $663.00M | $621.00M | $602.00M | 4.9% | -9.7% |
| Animal health diagnostics | $434.00M | $386.00M | $376.00M | $353.00M | $374.00M | $305.00M | $268.00M | $136.00M | $44.00M | $38.00M | 4.6% | +12.4% |
| Poultry | $432.00M | $527.00M | $524.00M | $476.00M | $507.00M | $537.00M | $559.00M | $522.00M | $479.00M | $457.00M | 4.6% | -18.0% |
| Dogs and Cats | $304.00M | $285.00M | $285.00M | $264.00M | $263.00M | $215.00M | $195.00M | $168.00M | $151.00M | $150.00M | 3.2% | +6.7% |
| Fish | $286.00M | $242.00M | $220.00M | $212.00M | $187.00M | $148.00M | $134.00M | $132.00M | $118.00M | $90.00M | 3.0% | +18.2% |
| Other non-pharmaceutical | $263.00M | $253.00M | $254.00M | $250.00M | $231.00M | $210.00M | $184.00M | $170.00M | $174.00M | $152.00M | 2.8% | +4.0% |
| Contract manufacturing & human health | $116.00M | $80.00M | $78.00M | $86.00M | $82.00M | $83.00M | $85.00M | $58.00M | $44.00M | $51.00M | 1.2% | +45.0% |
| Sheep and other | $88.00M | $82.00M | $100.00M | $98.00M | $95.00M | $76.00M | $72.00M | $83.00M | $84.00M | $79.00M | 0.9% | +7.3% |
| Medicated feed additives | $27.00M | $293.00M | $354.00M | $360.00M | $420.00M | $460.00M | $470.00M | $485.00M | $475.00M | $500.00M | 0.3% | -90.8% |
| Contract Manufacturing | – | – | – | – | – | – | – | – | $44.00M | $51.00M | – | – |
| Sheep and Other [Member] | – | – | – | – | – | – | – | – | $84.00M | $79.00M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total geographical area | $9.35B | $9.18B | $8.47B | $7.99B | $7.69B | $6.59B | $6.18B | $5.77B | $5.26B | $4.84B | 98.8% | +1.9% |
| United States | $5.10B | $5.07B | $4.56B | $4.31B | $4.04B | $3.56B | $3.20B | $2.88B | $2.62B | $2.45B | 53.8% | +0.5% |
| Other emerging markets | $913.00M | $865.00M | $784.00M | $758.00M | $778.00M | $656.00M | $647.00M | $634.00M | $657.00M | $607.00M | 9.6% | +5.5% |
| Other developed markets | $641.00M | $564.00M | $512.00M | $468.00M | $467.00M | $388.00M | $370.00M | $361.00M | $339.00M | $302.00M | 6.8% | +13.7% |
| Brazil | $393.00M | $414.00M | $393.00M | $330.00M | $312.00M | $258.00M | $293.00M | $295.00M | $300.00M | $245.00M | 4.2% | -5.1% |
| Australia | $329.00M | $319.00M | $323.00M | $289.00M | $259.00M | $207.00M | $196.00M | $189.00M | $176.00M | $157.00M | 3.5% | +3.1% |
| United Kingdom | $325.00M | $314.00M | $277.00M | $235.00M | $234.00M | $178.00M | $198.00M | $181.00M | $149.00M | $151.00M | 3.4% | +3.5% |
| Canada | $290.00M | $277.00M | $255.00M | $238.00M | $232.00M | $210.00M | $206.00M | $203.00M | $184.00M | $173.00M | 3.1% | +4.7% |
| Germany | $236.00M | $225.00M | $202.00M | $176.00M | $183.00M | $159.00M | $153.00M | $147.00M | $137.00M | $125.00M | 2.5% | +4.9% |
| China | $227.00M | $270.00M | $320.00M | $382.00M | $357.00M | $266.00M | $200.00M | $211.00M | $174.00M | $145.00M | 2.4% | -15.9% |
| France | $165.00M | $156.00M | $142.00M | $126.00M | $132.00M | $118.00M | $117.00M | $130.00M | $121.00M | $117.00M | 1.7% | +5.8% |
| Mexico | $160.00M | $169.00M | $162.00M | $136.00M | $133.00M | $116.00M | $117.00M | $100.00M | $86.00M | $76.00M | 1.7% | -5.3% |
| Japan | $154.00M | $147.00M | $158.00M | $173.00M | $186.00M | $177.00M | $158.00M | $149.00M | $138.00M | $127.00M | 1.6% | +4.8% |
| Spain | $145.00M | $130.00M | $122.00M | $118.00M | $128.00M | $112.00M | $114.00M | $110.00M | $93.00M | $82.00M | 1.5% | +11.5% |
| Chile | $139.00M | $123.00M | $140.00M | $141.00M | $136.00M | $100.00M | $91.00M | $76.00M | – | – | 1.5% | +13.0% |
| Italy | $137.00M | $129.00M | $121.00M | $111.00M | $115.00M | $90.00M | $112.00M | $104.00M | $89.00M | $83.00M | 1.4% | +6.2% |
| Other International Countries | – | – | – | – | – | – | – | – | – | $100.00M | – | – |
| International | – | – | – | – | – | – | – | – | – | $2.39B | – | – |
From the segment and revenue-disaggregation notes of Zoetis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.